Patent classifications
A
HUMAN NECESSITIES
Load children
A61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
Load children
A61K
PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
Load children
47/00
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/50
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/51
the non-active ingredient being a modifying agent
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/68
the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/6891
Pre-targeting systems involving an antibody for targeting specific cells
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/6899
Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
Filter patents View analytics View as hierarchy Open in page

A61K47/6899

Targeting and in vivo imaging of tumor-associated macrophages
09913920 · 2018-03-13 · ·

The disclosure relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
20170258935 · 2017-09-14 · ·

Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
09556273 · 2017-01-31 · ·

The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.